



ChemTech

**International Journal of ChemTech Research**  
CODEN(USA): IJCRGG, ISSN: 0974-4290, ISSN(Online):2455-9555  
Vol.10 No.10, pp385-393,2017

## **Teneligliptin: A Review on Therapeutic Role in Diabetics Mellitus**

**Vedantika Das<sup>1\*</sup>, Bhushan Bhairav<sup>1</sup>, R.B.Saudagar<sup>2</sup>**

<sup>1</sup>Department of Quality Assurance, R.G.Sapkal College of Pharmacy, Anjaneri, Nashik, MH, India

<sup>2</sup>Department of Pharmaceutical Chemistry, R.G.Sapkal College of Pharmacy, Anjaneri, NashikMH, India

**Abstract:** Diabetes challenges the global population, diabetic organizations across the globe call for unanimous resonance of *Diabetes Voice* to tackle diabetes with healthy living. With the discovery of new pathophysiology associated with diabetes, patients are gaining access to the newer therapeutic classes. Teneligliptin is a dipeptidyl peptidase-4 inhibitor, is indicated for the treatment of adults with type 2 diabetes (T2DM). It acts like an insulin/glucagon modulator controlling blood glucose over 24 hours. It is effective in tackling short-term glycemic fluctuations and improvement in  $\beta$ -cell parameters is observed soon after treatment. Half-life of 26.9 hours ensures once a day administration. This article reviews on clinical particulars, pharmacology, and therapeutic efficacy and tolerance of teneligliptin in the treatment of adults with T2DM. In patients with type 2 diabetics, treatment with teneligliptin produced clinically significant improvements in hemoglobin A1C, fasting plasma glucose (FPG) and 2-hour post-prandial glucose (PPG) compared to placebo. Teneligliptin, as a Dipeptidyl Peptidase-4 Inhibitor improves early-phase insulin secretion with Type 2 Diabetes and additionally its pleiotropic benefits of Cardio protection. A comprehensive comparison of Teneligliptin with other gliptins in the class & provides a concise summary of all clinical trials till the date with Teneligliptin monotherapy & combination with other ant-diabetic drugs.

**Keywords :** Teneligliptin, Pleiotropic benefits, Early-phase, Monotherapy.

**Vedantika Das et al**/International Journal of ChemTech Research, 2017,10(10): 385-393.

\*\*\*\*\*